Hiroshi Wakabayashi

9PUBLICATIONS
12CO-AUTHORS
Formal methods for softwareGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Cell physiologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 05, 2026
Validation of Simplified Renal Dosimetry Protocols for 177Lu-DOTATATE Therapy Using the IDAC-dose Software.

|Apr 01, 2026
High-dose ¹³¹I-metaiodobenzylguanidine therapy in relapsed high-risk neuroblastoma: a descriptive analysis of clinical outcomes and associated factors.

Hiroshi Wakabayashi, Rie Kuroda, Daiki Kayano

|Aug 06, 2025
Combination therapy of an 211At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy.

Hiroaki Echigo, Masayuki Munekane, Takeshi Fuchigami

|Jul 03, 2025
Positive Protective Effects of Sigma-1 Receptor Stimulation with Fluvoxamine after Myocardial Ischemia and Reperfusion in Rats.

Xue Zhang, Hiroshi Wakabayashi, Hiroshi Mori

|May 29, 2025
Dynamic expression of the myocardial sigma-1 receptor after doxorubicin cardiomyopathy using radioiodine-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5 V) imaging.

Zhuoqing Chen, Hiroshi Wakabayashi, Hiroshi Mori

|Nov 27, 2021
Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation.

Rie Kuroda, Hiroshi Wakabayashi, Raita Araki

Pageof 2

Frequent Collaborators

1 joint publications

Masayuki Munekane

1 joint publications

Takeshi Fuchigami

1 joint publications

Takashi Nakamura

1 joint publications

Atsushi Furukawa